Overview

Selective 2-AR Antagonism in Asthma

Status:
COMPLETED

Trial end date:
2022-08-16

Target enrollment:

Participant gender:

Summary

The objectives are to assess the safety, tolerability and effect on the airways of TR4 in patients with mild-to-moderate asthma. The Phase 1 trial is randomised, double-blind, placebo-controlled, and ascending-dose in design.

Phase:

PHASE1

Details

Lead Sponsor:

Trio Medicines Ltd.

Collaborator:

Hammersmith Medicines Research